We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Evaluate the Safety and Efficacy of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery (ENCASE-II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04086550
Recruitment Status : Recruiting
First Posted : September 11, 2019
Last Update Posted : January 18, 2022
Information provided by (Responsible Party):
Polyganics BV

Brief Summary:
The objective of the study is to clinically assess the safety and effectiveness of LIQOSEAL® as a means of reducing intra- as well as post-operative CSF leakage in patients undergoing elective cranial intradural surgery with a dural closure procedure to show noninferiority compared to a control group.

Condition or disease Intervention/treatment Phase
Cerebrospinal Fluid Leak Device: LIQOSEAL Device: DuraSeal, Adherus Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 228 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Randomized, Two-arm, Multicenter Study to Evaluate the Safety and Efficacy of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery
Actual Study Start Date : May 20, 2021
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : March 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Investigational arm
Application of LIQOSEAL after closure of dura mater
Adjunctive bioresorbable patch

Active Comparator: Control arm
Application of Adherus or DurSeal after closure of dura mater
Device: DuraSeal, Adherus
synthetic absorbable sealants

Primary Outcome Measures :
  1. Composite endpoint defined as successful dural repair without any of the following compared to the control group: intra-operative CSF leakage percutaneous CSF leak significant pseudomeningocele wound infection [ Time Frame: 30 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:


  1. Subjects who are able to provide written informed consent prior to participating in the clinical investigation.
  2. Subjects who are ≥ 18 years old.
  3. Subjects who are able to comply with the follow-up or other study requirements.
  4. Subjects wo are planned for elective surgery including a trepanation to reach the subdural infratentorial space (with lower limit of incision defined as the lower edge of C2) in whom a dural incision will be closed.
  5. Female subjects of child bearing potential must agree to use a form of contraception from the time of signing the informed consent form through 90 days post-surgery.


  1. Subjects with surgical wound classification Class I/Clean.
  2. Subjects with minimally 5 mm of dural space surrounding dural opening.

Exclusion Criteria:


  1. Female subjects who are pregnant or breastfeeding.
  2. Subjects with an assumed impaired coagulation due to medication or otherwise.
  3. Subjects suspected of an infection requiring antibiotics.
  4. Subjects with any type of dural diseases in planned dural closure area.
  5. Subjects requiring re-opening of planned surgical area within 90 days after surgery.
  6. Subjects with a known allergy to any of the components (Lactide-Caprolactone co-polyester; Butanediol-BDI co-polyurethane; Polyethylene glycol Succinimidyl Gluterate; Disodium hydrogen phosphate or D&C Green No 6) of LIQOSEAL®.
  7. Subjects who previously received a LIQOSEAL®.
  8. Subjects who previously participated in this study or any investigational drug or device study within 30 days of screening.
  9. Subjects with a presence of hydrocephalus.
  10. Subjects with contra-indication to MRI [cardiac pacemaker or defibrillator, severe claustrophobia, injured by a metallic object that was not removed, cochlear (ear) implants, metallic implants [e.g. knee replacement].


  1. Subjects in whom elevation of PEEP has a potential detrimental effect.
  2. Subjects who will require a CSF drain, electrodes or other devices passing the dural layer or extra to intracranial bypass surgery.
  3. Subjects who have primary closure of the dura mater with synthetic, nonautologous or autologous material other than galea.
  4. Subjects in whom no intra-operative CSF leakage is present after primary closure of the dura mater with elevation of PEEP.
  5. Subjects who after primary closure (including galea, if applicable) of the dura mater have a gap > 3 mm.
  6. Subjects whom dural opening size including 5 mm margin exceeds patch size (8 x 8 cm).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04086550

Layout table for location contacts
Contact: Andrew Carlson # 505 272 6094 AndrewCarlson@salud.unm.edu

Show Show 17 study locations
Sponsors and Collaborators
Polyganics BV
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Polyganics BV
ClinicalTrials.gov Identifier: NCT04086550    
Other Study ID Numbers: CIP-2
First Posted: September 11, 2019    Key Record Dates
Last Update Posted: January 18, 2022
Last Verified: January 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cerebrospinal Fluid Leak
Neurologic Manifestations
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System
Wounds and Injuries